Sander Slootweg

He currently serves on the boards of Forbion’s portfolio companies Xention Discovery Ltd, Provesica Ltd, Pulmagen Therapeutics, Ltd, Oxyrane Ltd and uniQure. In addition, Sander was responsible for two of Forbion’s recent exits: Biovex, Inc. was sold to Amgen in March of this year for up to USD 1 billion and Fovea Pharmaceutics SA was sold to sanofi-aventis for up to EUR 390 million in 2009. In recent years Sander has served on the boards of Argenta Discovery Ltd (sold to Galapagos in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella Cardiosystems AG (sold to Abiomed, Inc. in 2005), Glycart AG (sold to Roche in 2005), Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), Pieris AG and has acted as the Chairman of the Board of AMT N.V. (Amsterdam, Netherlands / Euronext: AMT). Before co-founding Forbion Capital Partners, he was an Investment Director at ABN AMRO Capital Life Sciences. His other activities at ABN AMRO included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami). Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands.

Sander Slootweg is the Founder, Co-owner & Managing Partner at Forbion Capital Partners, based in Europe. With a background in Venture Capital, Sander Slootweg has a rich history of leadership and innovation. Sander Slootweg studied MS Economics/Finance @ Vrije Universiteit Amsterdam. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.